Skip to main content
DrugPrice

Manufacturer Rebate

A post-sale discount paid by a drug manufacturer to a PBM or insurer in exchange for favorable formulary placement, reducing the effective net price below the list price.

How It Works

Manufacturer rebates are the single biggest reason U.S. drug list prices diverge from what payers actually pay. Rebates are paid quarterly from manufacturer to PBM based on utilization data, and their size scales with formulary placement: preferred-tier brands with tight step-therapy controls command rebates of 40-70% of WAC, while non-preferred drugs may get only 10-20%. Insulin analogs like NovoLog and Humalog were historically rebated over 70% off WAC, which is why net prices have been flat or declining even as list prices rose. For insulin, the Inflation Reduction Act capped Medicare patient insulin copays at $35/month beginning January 2023, and the American Rescue Plan plus subsequent manufacturer announcements pushed commercial insulin list prices down 70-78% in 2024 (Lilly, Novo Nordisk, Sanofi all cut Humalog/NovoLog/Lantus list prices). Humira rebates ran around 60% before biosimilar entry; the 2023 biosimilar wave (Amjevita, Cyltezo, Hyrimoz, eight others by year-end) disrupted that rebate pool. Rebates feed PBM spread pricing: the PBM may collect a $500 rebate, pass $300 to the health plan, keep $200 as administrative retention. The IRA requires Medicare Part D plans to pass through increasingly larger shares of rebates to beneficiaries at the point of sale starting with the 2025 Part D redesign, which is the single biggest structural change to the Part D rebate economy since 2006.

Related Terms

  • Wholesale Acquisition Cost (WAC), The manufacturer's list price for a drug sold to wholesalers, often called the "sticker price" before any rebates or discounts.
  • Pharmacy Benefit Manager (PBM), A company that acts as a middleman between drug manufacturers, insurers, and pharmacies, negotiating drug prices, managing formularies, and processing claims.
  • Formulary, A list of prescription drugs covered by an insurance plan, organized into tiers that determine how much the patient pays for each drug.
  • PBM Spread Pricing, A PBM business practice of charging a health plan more for a drug than the PBM reimburses the pharmacy, retaining the difference as profit.
  • Inflation Rebate Penalty, An IRA provision requiring drug manufacturers to pay Medicare rebates when a drug's price increases exceed general inflation (CPI-U) on a year-over-year basis.

Explore Drug Data

Most Expensive DrugsGeneric Drug WatchSearch All Drugs

About This Definition

This definition is part of the DrugPrice Drug Pricing Glossary, 49 terms explaining how prescription drug pricing works in the United States. All definitions are written in plain language for patients, caregivers, journalists, and healthcare professionals.

this entity is one of the U.S. Medicare prescription-drug pricing concepts that recurs across this site. The definition above is the technical answer; the paragraphs below add the practical context for how the concept connects to the CMS Medicare Part D Drug Spending data data behind every per-entity page on the site.

In the CMS Medicare Part D Drug Spending data data, this concept shapes one or more of the fields that drive the per-entity grades and rankings on this site. The methodology page describes which fields feed into which output; this glossary entry documents the underlying term.

Source: CMS Medicare Part D Spending, 2026.